Low-Grade Glioma Market Report 2026

The low-grade glioma market size has grown strongly in recent years. It will grow from $1.47 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to advancements in neuroimaging technologies, improved survival rates in low-grade glioma patients, increased neurosurgical intervention rates, growing awareness of brain tumor symptoms, expansion of oncology treatment centers.

The low-grade glioma market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing focus on molecular tumor profiling, rising investment in targeted oncology drugs, growing demand for less aggressive treatment options, expanding access to specialized neuro-oncology care, ongoing clinical trials for novel therapies. Major trends in the forecast period include rising focus on early diagnosis and monitoring, growing adoption of targeted drug therapies, increasing preference for multimodal treatment approaches, expansion of personalized treatment planning, rising long-term disease management strategies.

The increasing prevalence of brain tumors is anticipated to drive the growth of the low-grade glioma market in the coming years. A brain tumor is defined as an abnormal proliferation of cells within the brain or its surrounding tissues and may be either benign or malignant. The growing incidence of brain tumors can be attributed to factors such as greater exposure to radiation, environmental contaminants, genetic susceptibility, and an aging population. Low-grade glioma management supports brain tumor treatment through the use of advanced diagnostic methods and targeted therapeutic approaches, including surgery, radiation therapy, and chemotherapy, which help slow disease progression, maintain neurological function, and enhance patient outcomes, highlighting the importance of early diagnosis and personalized care for managing brain tumors with similar growth characteristics. For example, in October 2025, Cancer Australia, an Australia-based government agency, reported that in 2023, Australia recorded 1,597 deaths due to brain cancer, including 956 men and 641 women. By 2025, this figure is projected to increase slightly to 1,639 deaths, comprising 979 men and 660 women. The estimated lifetime risk of dying from brain cancer by the age of 85 in 2025 is 1 in 195 (0.51%), with a higher risk among males at 1 in 165 (0.61%) and a lower risk among females at 1 in 240 (0.42%). As a result, the rising incidence of brain tumors is contributing to the expansion of the low-grade glioma market.

Major players in the low-grade glioma market are emphasizing the adoption of combination therapies and targeted treatment approaches, including genetic alteration-based drugs, to strengthen their competitive position and improve outcomes for children with low-grade glioma. Genetic alteration drugs are a form of targeted therapy that act on specific genetic mutations or abnormalities within cells, enabling the treatment of conditions such as cancer by interrupting the signaling pathways responsible for uncontrolled cell proliferation. For example, in May 2024, Day One Biopharmaceuticals, a U.S.-based biotechnology company, introduced Tovorafenib (Ojemda) following accelerated approval from the FDA. This targeted therapy is intended for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) associated with BRAF gene alterations. As a once-weekly oral treatment, it fulfills a significant unmet need among pediatric LGG patients who previously had limited therapeutic options.

In July 2024, Ipsen Biopharmaceuticals Inc., a U.S.-based pharmaceutical company, partnered with Day One Biopharmaceuticals Inc. to commercialize tovorafenib for the treatment of pediatric low-grade glioma (pLGG) associated with BRAF mutations. The collaboration is intended to broaden global access to the therapy by utilizing Ipsen’s oncology capabilities and international presence to support regulatory and commercial activities outside the U.S. Day One Biopharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused primarily on the development of targeted treatments for pediatric low-grade glioma.

Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc.

North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the low-grade glioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the low-grade glioma market by increasing costs related to imported oncology drugs, diagnostic imaging equipment, and specialized treatment technologies. These impacts are more evident in targeted therapy drug segments and advanced radiation systems, particularly in regions such as asia-pacific and europe that depend on global medical supply chains. Higher costs have affected hospital procurement and treatment affordability. However, tariffs have encouraged local manufacturing of oncology drugs, regional sourcing, and investment in domestic pharmaceutical capabilities, supporting long-term market sustainability.

The low-grade glioma market research report is one of a series of new reports that provides low-grade glioma market statistics, including low-grade glioma industry global market size, regional shares, competitors with a low-grade glioma market share, detailed low-grade glioma market segments, market trends and opportunities, and any further data you may need to thrive in the low-grade glioma industry. This low-grade glioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Low-grade gliomas are a type of brain tumor that originates from glial cells, which provide support and insulation to nerve cells in the brain. They are characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still lead to significant neurological symptoms and may require treatment.

The main drug types for low-grade glioma include trametinib, dabrafenib, ivosidenib, and mirdametinib. Trametinib is a medication used to treat certain cancers by inhibiting the MEK1/2 proteins involved in cancer cell growth. Treatment of low-grade glioma typically involves a combination of surgery, chemotherapy, and radiation. Medications are administered through various routes, including oral and topical methods, and are distributed via multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The low-grade glioma market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, and targeted therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The low-grade glioma market also includes sales of astrocytomas, oligodendrogliomas, and ependymomas. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.